773 related articles for article (PubMed ID: 28325524)
1. Current status of lipid management in acute coronary syndrome.
Fujisue K; Tsujita K
J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524
[TBL] [Abstract][Full Text] [Related]
2. Lipid management in ACS: Should we go lower faster?
Gencer B; Mach F
Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
[TBL] [Abstract][Full Text] [Related]
3. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
5. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
[TBL] [Abstract][Full Text] [Related]
7. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
[TBL] [Abstract][Full Text] [Related]
8. Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.
Nakamura M; Uno K; Hirayama A; Ako J; Nohara A; Arai H; Harada-Shiba M
BMJ Open; 2017 Jul; 7(6):e014427. PubMed ID: 28674132
[TBL] [Abstract][Full Text] [Related]
9. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
10. Treatment of dyslipidemia in acute coronary syndrome.
Yadav S; Sawhney JPS
Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S51-S57. PubMed ID: 38307382
[TBL] [Abstract][Full Text] [Related]
11. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
12. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
15. [Management of hypercholesterolemia in patients with acute coronary syndrome: current mechanisms and future perspectives].
Lettino M
G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):31S-7. PubMed ID: 27312021
[TBL] [Abstract][Full Text] [Related]
16. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
Auer J; Berent R
Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
18. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
[TBL] [Abstract][Full Text] [Related]
19. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
20. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
Reklou A; Katsiki N; Karagiannis A; Athyros V
Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]